• Brothers C, Cutrell A, Zhao H et al. (2005) Once daily administration of abacavir is not a clinical risk factor for suspected hypersensitivity reactions in clinical trials and rash alone is not sufficient to diagnose the reaction. 12th Conference on Retroviruses and Opportunistic Infections, Boston, Abstract 836.
  • Cao K, Hollenback J, Shi X, Shi W, Chopek M & Fernandez-Vina MA (2001) Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Human Immunology 62, 10091030.
  • Cao K, Moormann AM, Lyke KE et al. (2004) Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci. Tissue Antigens 63, 293325.
  • DART Trial Team (2008) Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). Tropical Medicine and International Health 13, 616.
  • DART Trial Team (2010) Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375, 123131.
  • Hughes AR, Mosteller M, Bansal AT et al. (2004) Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 5, 203211.
  • Hughes AR, Spreen WR, Mosteller M et al. (2008) Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. The Pharmacogenomics Journal 8, 365374.
  • Mallal S, Phillips E, Carosi G et al. (2008) HLA-B*5701 screening for hypersensitivity to abacavir. New England Journal of Medicine 358, 568579.
  • Meyer D, Singe RM, Mack SJ, Lancaster A, Nelson MP & Erlich H (2007) Single locus polymorphism of classical HLA genes. In: Immunobiology of the Human MHC: Proceedings of the 13th International Histocompatibility Workshop and Conference (ed. JAHansen) IHWG Press, Seattle.
  • Middleton D, Menchaca L, Rood H & Komerofsky R (2003) New allele frequency database: Tissue Antigens 61, 403407.
  • Park WB, Choe PG, Song KH et al. (2009) Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir? Clinical Infectious Diseases 48, 365367.
  • Prins JM, Rauch A, Bergin C, Ristola M, Branco T & Pearce HC (2008) CNA110329: a prospective epidemiological study to determine the prevalence of HLA-B*5701 in HIV-infected individuals in five European countries. Journal of the International AIDS Society 11, 155.
  • Rauch A, Nolan D, Martin A, McKinnon E, Almeida C & Mallal S (2006) Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clinical Infectious Diseases 43, 99102.
  • Saag M, Balu R, Phillips E et al. (2008) High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clinical Infectious Diseases 46, 11111118.
  • WHO (2009) WHO/UNAIDS. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress Report 2009. Available at
  • Zucman D, Truchis P, Majerholc C, Stegman S & Caillat-Zucman S (2007) Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. Journal of the Acquired Immune Deficiency Syndrome 45, 13.